Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-11-25

FDA Approved: LEVETIRACETAM — Supplemental Application (Lupin Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved Lupin Pharmaceuticals' supplemental application for levetiracetam, granting approval of a generic anti-epileptic drug.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LEVETIRACETAM (levetiracetam)

Snippet

SUPPL AP for LEVETIRACETAM (LEVETIRACETAM)